---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002117"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:50:12.253240+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coherus supplements proxy for UDENYCA sale; discloses JPMorgan valuation & cash flow projections

## Summary
- Four shareholder complaints filed in NYC Supreme Court alleging proxy deficiencies; company denies merit.
- Voluntarily adds JPMorgan's selected transaction analysis: implied consideration ~$530M (base plus risk-adjusted earnout).
- Discloses UDENYCA unlevered free cash flow: $51M in 2025E, rising to $105M by 2029E, with revenue $186M in 2025E.
- Special meeting to approve sale to Intas Pharmaceuticals remains scheduled for March 11, 2025.
- Company believes no supplemental disclosures are legally required but provides them to avoid litigation delay.

## SEC filing metadata
- accession: 0001558370-25-002117
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837025002117/0001558370-25-002117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837025002117/chrs-20250304x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002117
- JSON: https://secwatch.observer/filing/0001558370-25-002117.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.